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Research Article 
 
Novelty and impact:  
Surgery is the mainstay curative treatment in most solid cancer types. This study found that 
cancer surgery performed during holiday periods is associated with worse prognosis than for 
non-holiday periods for several cancer sites, particularly for cancer of the breast and liver-
pancreas-bile ducts, and in sub-groups of cancer of the colon-rectum, head-and-neck, 
prostate, kidney-urine bladder, and thyroid. These findings highlight the importance of 
maintaining sufficient surgical expertise for certain cancer procedures during holiday 
periods.   
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Abstract  
Surgery is the mainstay curative treatment in most cancer. We aimed to test the new 
hypothesis that cancer surgery performed during holiday periods is associated with worse 
long-term prognosis than for non-holiday periods. This nationwide Swedish population-
based cohort study included 228,927 patients during 1997-2014 who underwent elective 
resectional surgery for a cancer where the annual number of resections was over 100. The 
16 eligible cancer sites were grouped into 10 cancer groups. The exposure, holiday periods, 
was classified as wide (14-weeks) or narrow (7-weeks). Surgery conducted inside versus 
outside holiday periods was compared regarding overall disease-specific (main outcome) 
and overall all-cause (secondary outcome) mortality. Cox regression provided hazard ratios 
(HR) with 95% confidence intervals (CI) adjusted for age, sex, comorbidity, hospital volume, 
calendar period, and tumor stage. Surgery conducted during wide and narrow holiday 
periods were associated with increased HRs of disease-specific mortality for cancer of the 
breast (HR 1.08, 95% CI 1.03-1.13 and HR 1.06, 95% CI 1.01-1.12) and possibly of cancer of 
the liver-pancreas-bile ducts (HR 1.09, 95% CI 0.99-1.20 and HR 1.12, 95% CI 0.99-1.26). Sub-
groups with cancer of the colon-rectum, head-and-neck, prostate, kidney-urine bladder, and 
thyroid also experienced statistically significantly worse prognosis following surgery 
conducted during holiday periods. No influence of surgery during holiday was detected for 
cancer of the esophagus-stomach, lung, or ovary-uterus. All-cause HRs were similar to the 
disease-specific HRs. The prognosis following cancer surgery might not be fully maintained 
during holiday periods for all cancer sites.   
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Introduction 
Cancer is a major public health concern and the overall cancer incidence is increasing.1 
Despite all efforts to add and improve non-surgical cancer treatments, surgery remains the 
primary curative treatment for most solid carcinomas.2 Of the 15.2 million individuals 
diagnosed with cancer in 2015 worldwide, over 80% needed surgery.2 Cancer surgical 
research has often focused on short-term outcomes, and the 30-day mortality rate has 
reduced to <5% even for extensive cancer procedures. The vast majority of patients who die 
within 5 years of cancer surgery die from tumor recurrence, however, and in terms of saved 
lives in cancer there is much to gain from improving the long-term prognosis. It is known 
that annual surgery volume strongly influences the prognosis of some cancers,3, 4 but 
otherwise, research examining opportunities for improvements in surgical strategies 
is limited. The hypothesis of the present study was that the timing of cancer surgery within 
holiday periods negatively influences long-term prognosis. To the best of our knowledge 
there are no previous studies that have tested this hypothesis. During holiday periods the 
availability of surgeons with expertise and experience in certain cancer procedures might be 
limited or absent in some hospitals, which may result in worse outcomes after cancer 
surgery. In Sweden, the holiday periods (mid-June to end of August and mid-December to 
mid-January) are more distinct than in most other countries, making this country an ideal 
base for the present study. With the aim of evaluating the association between the timing of 
major cancer surgery regarding holiday periods and long-term prognosis, we therefore 
conducted a nationwide Swedish study including all common cancer groups where surgery is 
the primary therapy.  
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Methods 
Design  
This was a population-based nationwide Swedish cohort study conducted during the period 
January 1, 1997 to December 31, 2014. We followed a detailed study protocol finalized 
before initiation of any analyses. The study exposure was the timing of cancer surgery within 
or outside holiday periods. The main outcome was overall disease-specific mortality, while 
overall all-cause mortality was the secondary outcome. Included in the cohort were patients 
who had undergone elective resectional surgery for cancer sites where surgery is the 
primary treatment. The data sources were high-quality and complete nationwide Swedish 
registers for cancer (Cancer Registry), all diagnoses and surgical procedures (Patient 
Registry), and mortality (Causes of Death Registry). Accurate linkage of each participant’s 
information between registers was possible through the unique 10-digit personal identity 
number given to all Swedish residents upon birth or immigration. This identifier has been 
validated as a highly robust tool for linkages in register-based research.5 The study was 
approved by the Regional Ethical Review Board in Stockholm (2015/1916-31/1). 
 
Cohort 
Selected as cohort members were adult patients (at least 18 years) who had undergone 
elective (planned) surgical resection corresponding in site and time with the primary cancer 
diagnosis. Only carcinomas of sites where a yearly average of at least 100 operations was 
conducted in Sweden during the study period were included. Resectional surgery was 
identified from the Swedish Patient Registry and cancer diagnoses were retrieved from the 
Swedish Cancer Registry. The operations were defined by codes in the Swedish Classification 
of Surgical Procedures from 1997 onwards. Sixteen eligible cancer sites were identified: 
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esophagus, stomach, liver, pancreas, bile ducts, colon, rectum, head-and-neck, lung, thyroid, 
breast, kidney, urine bladder, prostate, ovary, and uterus. These were further combined into 
10 cancer groups on the basis of anatomical proximity, shared clinical characteristics 
(diagnostic procedures, treatment, and prognosis), and surgical sub-specialty performing the 
operations: esophagus-stomach, liver-pancreas-bile ducts, colon-rectum, head-and-neck, 
lung, thyroid, breast, kidney-urine bladder, prostate, and ovary-uterus. 
 
Exposure  
The study exposure was the timing of surgery within or outside holiday periods. We 
considered two holiday periods, one representing a 14-week “wide holiday period” from 
June 16 to August 31 and December 16 to January 7, and one representing a 7-week “narrow 
holiday period”, from June 25 to August 15. The narrow holiday period corresponded to a 
holiday period in Sweden when most healthcare staff members have holidays, i.e. 
representing the most ‘under-staffed period’, while the wide holiday period corresponded to 
a time period when many healthcare staff members in Sweden have holiday, but the under-
staffing is not as heavy as during the narrow holiday period. In other words, the narrow 
holiday period is supposed to represent an exposure of higher specificity and lower 
sensitivity, while the wide holiday period is meant to represent an exposure period of lower 
specificity and higher sensitivity. Data on the exposure (date of surgery) were retrieved from 
the Patient Registry.  
 
Outcomes 
The main study outcome was overall disease-specific mortality, defined as a death where the 
tumor diagnosis of the same type as the one operated for was listed as a cause of death 
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from surgery to end of study period. The secondary outcome was overall all-cause mortality, 
defined as the date of death from any cause during the same period of follow-up. Data on 
the outcomes were retrieved from the Swedish Causes of Death Registry. 
 
Covariates 
Six well-established prognostic factors were considered as potential confounders: age, sex, 
comorbidity, annual hospital volume, calendar year of surgery, and tumor stage. Information 
about age and sex were available in all registers. Comorbidities were defined and 
categorized according to the most updated version of the well-validated Charlson 
comorbidity index.6 Data on comorbidity, annual hospital volume, and calendar year of 
surgery were collected from the Patient Registry. The seventh version of the Union for 
International Cancer Control TNM-classification was used for tumor staging.7 Tumor stage 
was available from the year 2004 onwards in the Cancer Registry.  
 
Validity of the data sources 
The Swedish Cancer Registry was initiated in 1958. The completeness of recording all new 
cancers in this registry is 96%,8 and is nearly 100% in patients who undergo surgery. Data on 
tumor stage have excellent completeness (98%) and concordance (98%) for surgically 
resected cancer.9  
 
The Swedish Patient Registry contains data on all in-hospital diagnoses and surgical 
procedures in Sweden since 1987.10 The variables representing dates and types of cancer 
surgery have almost 100% positive predictive values compared to operation charts.11, 12 The 
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diagnoses defining comorbidities in the Charlson comorbidity index have excellent 
nationwide coverage and positive predictive values of up to 95%.10 
 
The Swedish Causes of Death Registry has 99% completeness for causes of deaths and 100% 
completeness of dates of deaths for all deceased Swedish residents since 1952.13 
 
Statistical analysis 
Surgery conducted during wide and narrow holiday periods (with dates presented above) 
was analyzed in relation to risk of mortality, using non-holiday periods as the reference 
category. Each of the 10 cancer groups was analyzed separately. Cox regression analysis 
provided crude and multivariable adjusted hazard ratios (HR) with 95% confidence intervals 
(CI). The prognostic factors included in the full model (with categorizations) were: age at 
surgery (continuous variable), sex (male or female), comorbidity (Charlson comorbidity index 
0, 1-2, or ≥3), hospital volume (in quartiles for each cancer group), and calendar period of 
surgery (1997-2002, 2003- 2008, or 2009-2014). Additionally, tumor stage (I-II or III-IV) was 
added to the multivariable model in a sensitivity analysis for the period 2004-2014 when this 
variable was available. Missing data on tumor stage were managed by complete case 
analysis. Stratified analyses were performed for the five covariates with complete data, 
which were dichotomized to preserve statistical power as: age <65 years and ≥65 years, 
male and female sex, Charlson comorbidity index 0 and ≥1, hospital volume quartiles 1-2 and 
3-4, and calendar year 1997-2005 and 2006-2014. There were no losses to follow-up. 
Kaplan-Meier curves showing crude survival data were plotted for selected tumors. An 
experienced biostatistician (FM) conducted all data management and statistical analyses, 
and used the statistical software SAS version 9.4 (SAS Institute, Cary, NC).   
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Results 
Patients 
The study included 228,927 patients who underwent cancer surgery. Of these, 49,897 
patients (21.8%) had their surgery during the wide holiday period. Characteristics of the 
study participants are presented in Table 1. There were no major differences in the 
distribution of age, sex, comorbidity score, annual hospital volume, or calendar period of 
surgery for patients operated during and outside of wide holiday periods in any of the 10 
cancer groups.  
 
Esophago-gastric cancer 
Surgery conducted during wide or narrow holiday periods were not associated with any 
increased mortality in esophago-gastric cancer in the overall analyses, compared to surgery 
outside holiday periods (Table 2 and 3). The adjusted disease-specific HR was 1.00 (95% CI 
0.93-1.07) for wide holiday periods and 0.98 (95% CI 0.89-1.07) for narrow holiday periods. 
Similarly, the stratified analyses showed no associations (Table 4).  
 
Liver-pancreas-biliary cancer 
Surgery for liver-pancreas-biliary cancer during holiday periods was associated with an 
increased HRs of mortality of borderline statistical (Table 2 and 3, Supplementary Figure 1). 
The adjusted disease-specific HR was 1.09 (95% CI 0.99-1.20) for wide holiday periods and 
1.12 (95% CI 0.99-1.26) for narrow holiday periods. The corresponding HRs for disease-
specific mortality were increased in men (HR 1.22, 95% CI 1.08-1.39 and HR 1.21, 95% CI 
1.02-1.43, respectively) and in patients with comorbidity (HR 1.17, 1.02-1.35 and HR 1.25, 
95% CI 1.05-1.48) (Table 4).  
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Colorectal cancer 
Surgery conducted during wide and narrow holiday periods was not associated with 
increased HRs of mortality in colorectal cancer in the overall analyses (Table 2 and 3), with 
adjusted disease-specific HR of 1.02 (95% CI 0.99-1.05) for wide holiday periods and 1.00 
(95% CI 0.96-1.04) for narrow holiday periods. However, the stratified analyses of surgery 
conducted during narrow holiday periods showed increased HRs of disease-specific mortality 
in patients with comorbidity (HR 1.08, 95% CI 1.01-1.15) and in those operated during the 
later calendar period (HR 1.08, 95% CI 1.01-1.15) (Table 4). 
 
Head-neck cancer 
Surgery conducted during wide and narrow holiday periods was not associated with 
increased HRs of mortality in head-and-neck cancer in the overall analyses (Table 2 and 3). 
The adjusted disease-specific HR was 1.05 (95% CI 0.93-1.18) for wide holiday periods and 
1.02 (95% CI 0.88-1.19) for narrow holiday periods. However, in hospitals with lower annual 
volume the disease-specific HRs were increased for surgery conducted during wide (HR 1.31, 
95% CI 1.09-1.56) and narrow (HR 1.25, 95% CI 1.01-1.57) holiday periods (Table 4). 
 
Lung cancer 
Surgery conducted during wide and narrow holiday periods was not associated with 
increased HRs of mortality in lung cancer in the overall analyses, although all HRs were 
above 1.0 (Table 2 and 3). The adjusted disease-specific HR was 1.10 (95% CI 0.97-1.26) for 
wide holiday periods and 1.07 (95% CI 0.91-1.25) for narrow holiday periods. Similarly, the 
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stratified analyses revealed no statistically significant associations, although all HRs were 
above 1.0 (Table 4).  
 
Thyroid cancer 
Surgery conducted during wide and narrow holiday periods was not associated with 
increased HRs of mortality in thyroid cancer in the overall analyses, although all HRs were 
above 1.0 (Table 2 and 3). The adjusted disease-specific HR was 1.19 (95% CI 0.95-1.48) for 
wide holiday periods and 1.27 (95% CI 0.95-1.69) for narrow holiday periods. The stratified 
analyses showed an increased disease-specific HR following surgery during the narrow 
holiday period in patients without comorbidity (HR 1.44, 95% CI 1.01-2.06), and all other 
point HRs were above 1.0 (Table 4).  
 
Breast cancer 
Surgery for breast cancer during holiday periods was associated with increased HRs of 
mortality in the overall analyses (Table 2 and 3, Supplementary Figure 2). The adjusted 
disease-specific HR was 1.08 (95% CI 1.03-1.13) for wide holiday periods and 1.06 (95% CI 
1.01-1.12) for narrow holiday periods. The associations were similar between stratification 
variable categories (Table 4). 
 
Kidney-bladder cancer 
Surgery conducted during wide and narrow holiday periods was not associated with 
increased HRs of mortality in kidney-bladder cancer in the overall analyses (Table 2 and 3). 
The adjusted disease-specific HR was 1.10 (95% CI 1.01-1.20) for wide holiday periods and 
1.05 (95% CI 0.94-1.17) for narrow holiday periods. The stratified analyses revealed 
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increased HRs of disease-specific mortality in men (HR 1.14, 95% CI 1.02-1.27), in hospitals of 
higher annual volume (HR 1.22, 95% CI 1.09-1.37), and in surgery performed during a later 
calendar period (HR 1.27, 95% CI 1.11-1.44) (Table 4).  
 
Prostate cancer 
Surgery conducted during wide and narrow holiday periods was not associated with 
increased HRs of mortality in prostate cancer in the overall analyses (Table 2 and 3). The 
adjusted disease-specific HR was 0.97 (95% CI 0.78-1.20) for wide holiday periods and 1.10 
(95% CI 0.83-1.46) for narrow holiday periods. The only statistically significant association in 
the stratified analyses was an increased HR of disease-specific mortality following surgery 
conducted in wide holiday periods during the calendar period 2006-2014 (HR 1.63, 95% CI 
1.07-2.47) (Table 4).  
 
Ovary-uterus cancer 
Surgery conducted during wide and narrow holiday periods was not associated with 
increased HRs of mortality in ovary-uterus cancer in the overall analyses (Table 2 and 3). The 
adjusted HR of disease-specific mortality was 1.02 (95% CI 0.97-1.08) for wide holiday 
periods and 0.96 (95% CI 0.90-1.03) for narrow holiday periods. The stratified analyses did 
not reveal any statistically significant associations (Table 4).  
 
Sensitivity analyses for tumor stage 
In analyses of the sub-group of patients with data on tumor stage, the HRs were very similar 
with and without adjustment for tumor stage for all 10 cancer groups (data not shown).  
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Discussion 
This study indicates that surgery performed during holiday periods increases the overall 
mortality in cancer of the breast and of the liver-pancreas-bile ducts, but also in sub-groups 
of patients with cancer of the colon-rectum, head-neck, prostate, kidney-urine bladder, and 
thyroid. No associations were found for surgery for cancer of the esophagus-stomach, lung, 
or ovary-uterus. 
 
The population-based design with inclusion of virtually all patients in Sweden who 
underwent elective surgery of common cancers during the study period counteracted 
selection bias, made it possible to compare results between cancer groups, and provided 
large sample sizes. The personal identity numbers available for all Swedish residents enabled 
complete follow-up of all patients. The distinct holiday periods in Sweden provided a good 
exposure classification, and the accurate and objective assessment of both the exposure 
(timing of surgery) and outcome (mortality) also counteracted information bias. 
Confounding is a source of error in observational studies in general, but might of less 
concern in this study because cancer surgery is conducted without unnecessary delays and 
there is no factor that would obviously influence whether the surgery is conducted outside 
or inside holiday periods. Nevertheless, the results were adjusted for six prognostic factors 
resulting in negligible changes, documenting absence of confounding by these factors. The 
many tests performed increase the risk of chance errors (type I). Therefore, we reduced the 
number of tests by combining cancer sites into fewer groups, a strategy that also improved 
the statistical precision. Yet, it is possible that some of the increased HRs of the sub-group 
analyses are chance findings, but no single HR of mortality was statistically significantly 
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decreased for cancer surgery conducted during holiday periods, indicating consistency of the 
findings.  
 
The increased mortality associated with the timing of certain cancer procedures during 
holiday periods might suggest that the expertise of the available surgeons and other 
healthcare staff is decreased for some procedures during these periods, at least in Sweden. 
However, it was not possible to measure the level of availability of surgical expertise in this 
study. These results might not be readily generalizable to other populations, at least not to 
countries where the healthcare is organized in a different fashion from Sweden. To the best 
of our knowledge, there is only one previous study examining how cancer surgery conducted 
during holiday periods influences the prognosis, i.e. our study examining esophageal cancer 
in a different cohort study, which found no association,14 which is in agreement with the 
results of esophago-gastric cancer in the present study. Thus, further studies on this topic 
within other populations are warranted before any general clinical recommendations can be 
considered. If confirmed in future studies, however, these findings highlight a need for 
careful holiday planning for surgeons whose expertise cannot be easily replaced.  
 
There is a need for studies examining the mechanisms behind the findings of this study. We 
can only speculate about explanations. Mammography screening may be less intense during 
holiday periods, and screen detected breast tumors are more likely to be of earlier stages 
with better prognosis, while symptomatic breast cancers with worse prognosis may more 
often undergo surgery during holiday periods. However, the association remained in 
analyses adjusted for tumor stage, which argue against this mechanism. Regarding cancer of 
the liver-pancreas-biliary tract, and also other tumors where associations were indicated, 
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more advanced tumors with worse prognosis might need to undergo surgery during holiday 
periods, while less advanced cases may more often be able to wait until after holiday 
periods. But again, the association remained after adjustment for tumor stage arguing 
against this explanation. Another potential explanation for the differences in prognosis 
between certain cancers is differences in how the surgical sub-specialites deal with the 
potential “holiday problem”. Less experienced surgeons might be allowed to take on 
procedures for some cancer types without the optimal support, e.g. breast cancer, and not 
in others, e.g. cancer of the oesophagus and stomach. We know from own experience that 
an systematic collaboration to ascertain the surgical competence in surgery for esophageal 
cancer during holiday periods is in place in Sweden. Patients are readily referred to another 
hospital whenever the optimal surgical expertise is not available.14 Regarding cancer of the 
liver-pancreas-biliary tract the differences in prognosis might be due to surgeons with less 
extensive surgical training in these specific procedures still may need to conduct some of 
these operations without the support from the most experienced surgeons. Regarding the 
decreased prognosis in some sub-groups of other cancer types, variations in surgeons’ 
experience and the lack of the optimal expertise during holiday periods might help explain 
these findings. The findings of this study indicate that an organized collaboration between 
hospitals might be warranted for cancer surgery in general, and particularly for cancer of the 
breast and liver-pancreas-bile ducts. An alternative strategy might be to ask surgeons with 
the appropriate experience and expertise to conduct or assist the operation at another 
hospital.  
 
In conclusion, this population-based study of nearly a quarter of a million patients who 
underwent surgery for cancer in Sweden indicates that the timing of surgery during holiday 
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periods might negatively influence the prognosis for cancer of the breast and possibly also 
for cancer of the liver-pancreas-bile ducts. Sub-groups of patients with cancer of the colon-
rectum, head-neck, prostate, kidney-urine bladder, and thyroid might also be at increased 
risk of increased mortality, while no associations were found for cancer of the esophagus-
stomach, lung, or ovary-uterus. If confirmed in future research, these findings might indicate 
the importance of maintaining sufficient surgical expertise for certain cancer procedures 
during holiday periods.  
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Table 1. Characteristics of 228,927 patients who underwent surgery for 10 common cancer groups in 1997-2014 in Sweden.  
 
 
* Wide holiday period is from 16th June to 31st August and 16th December to 7th January. 
†Standard deviation. 
  
Cancer  Wide 
holiday 
period
* 
Total Age Sex Charlson comorbidity score Hospital volume (quartiles) Calendar period 
Mean 
(SD)† 
Male 
N (%) 
Female 
N (%) 
0 
N (%) 
1 
N (%) 
≥2 
N (%) 
I 
N (%) 
II 
N (%) 
III 
N (%) 
IV 
N (%) 
1997-2002 
N (%) 
2003-2008 
N (%) 
2009-2014 
N (%) 
Esophago-
gastric 
No 4656 68 (11) 3076 (77) 1580 (75) 2759 (76) 1167 (77) 730 (75) 1159 (77) 1144 (73) 974 (77) 1379 (77) 1595 (75) 1516 (76) 1545 (77) 
Yes 1468 69 (11) 941 (23) 527 (25) 883 (24) 346 (23) 239 (25) 356 (23) 415 (27) 296 (23) 401 (23) 520 (25) 477 (24) 471 (23) 
Liver-pancreas-
biliary  
No 3102 65 (10) 1622 (77) 1480 (75) 1641 (76) 921 (76) 540 (77) 777 (78) 694 (77) 592 (75) 1039 (76) 594 (76) 872 (76) 1636 (76) 
Yes 971 65 (10) 473 (23) 498 (25) 519 (24) 291 (24) 161 (23) 223 (22) 212 (23) 200 (25) 336 (24) 185 (24) 271 (24) 515 (24) 
Colorectal No 45667 71 (11) 23547 (75) 22120 (75) 27298 (75) 10977 (75) 7392 (76) 11217 (76) 11593 (75) 10621 (75) 12236 (74) 12428 (75) 14769 (75) 18470 (75) 
Yes 15232 71 (11) 7809 (25) 7423 (25) 9179 (25) 3657 (25) 2396 (24) 3626 (24) 3851 (25) 3453 (25) 4302 (26) 4169 (25) 4834 (25) 6229 (25) 
Head-neck No 4076 63 (13) 2526 (76) 1550 (78) 2635 (76) 905 (77) 536 (77) 818 (77) 1068 (76) 456 (77) 1734 (77) 931 (76) 1301 (78) 1844 (76) 
Yes 1247 64 (13) 808 (24) 439 (22) 816 (24) 269 (23) 162 (23) 250 (23) 340 (24) 134 (23) 523 (23) 301 (24) 368 (22) 578 (24) 
Lung No 1877 65 (9) 938 (73) 939 (75) 1033 (75) 529 (72) 315 (74) 406 (75) 405 (73) 549 (74) 517 (73) 486 (73) 585 (75) 806 (74) 
Yes 660 65 (9) 349 (27) 311 (25) 346 (25) 202 (28) 112 (26) 133 (25) 149 (27) 190 (26) 188 (27) 177 (27) 196 (25) 287 (26) 
Thyroid No 3843 52 (17) 1045 (81) 2798 (82) 3035 (82) 542 (80) 266 (83) 964 (85) 993 (82) 665 (80) 1221 (80) 804 (81) 1065 (83) 1974 (82) 
Yes 848 54 (18) 239 (19) 609 (18) 660 (18) 135 (20) 53 (17) 164 (15) 219 (18) 169 (20) 296 (20) 184 (19) 216 (17) 448 (18) 
Breast No 61050 63 (13) - 61050 (77) 47502 (77) 9491 (78) 4057 (77) 15032 (79) 14704 (77) 13751 (77) 17563 (76) 16998 (77) 19384 (78) 24668 (77) 
Yes 17774 63 (13) - 17774 (23) 13809 (23) 2724 (22) 1241 (23) 4033 (21) 4316 (23) 4000 (23) 5425 (24) 5018 (23) 5548 (22) 7208 (23) 
Kidney-bladder No 7026 66 (11) 4208 (77) 2818 (78) 4213 (77) 1775 (78) 1038 (79) 1608 (79) 1748 (78) 1674 (76) 1996 (78) 1866 (77) 2303 (77) 2857 (78) 
Yes 2018 66 (11) 1225 (23) 793 (22) 1262 (23) 487 (22) 269 (21) 425 (21) 493 (22) 526 (24) 574 (22) 544 (23) 684 (23) 790 (22) 
Prostate 
 
No 23911 63 (5) 23911 (84) - 18822 (84) 4046 (85) 1043 (83) 5727 (85) 5821 (85) 5395 (84) 6968 (83) 2263 (83) 8479 (85) 13169 (83) 
Yes 4570 63 (6) 4570 (16) - 3635 (16) 725 (15) 210 (17) 1028 (15) 1056 (15) 1046 (16) 1440 (17) 455 (17) 1476 (15) 2639 (17) 
Ovary-uterus 
 
No 21804 64 (13) - 21804 (75) 16432 (76) 3744 (74) 1628 (74) 5241 (77) 5093 (75) 5565 (75) 5905 (75) 6071 (75) 7168 (75) 8565 (75) 
Yes 7127 64 (13) - 7127 (25) 5281 (24) 1283 (26) 563 (26) 1592 (23) 1673 (25) 1875 (25) 1987 (25) 2007 (25) 2337 (25) 2783 (25) 
18 
 
Table 2. Wide holiday period (14-week period, 16th June to 31st August and 16th December to 7th 
January) of cancer surgery and risk of overall mortality, expressed as hazard ratio (HR) with 95% 
confidence interval (CI).  
Cancer  Wide 
holiday 
period 
Patients 
Number (%) 
Disease-specific mortality All-cause mortality 
Crude HR (95% 
CI) 
Adjusted HR 
(95% CI)* 
Crude HR (95% 
CI) 
Adjusted HR 
(95% CI)* 
Esophago-
gastric 
No   4656 (76)                                                                                                                                                                                              1.00 (reference)                                                                                                                                                      1.00 (reference)                                            1.00 (reference)                                              1.00 (reference)                                                                                      
Yes   1468 (24)                                                                                                                                                                                              1.01 (0.93-1.08)                              1.00 (0.93-1.07)                                    1.01 (0.95-1.09)                                                                            1.00 (0.94-1.07)                                                                                          
       
Liver-pancreas-
biliary  
No   3102 (76)                                                                                                                                                                                              1.00 (reference)                                                                                                                                                      1.00 (reference)                                            1.00 (reference)                                              1.00 (reference)                                                                                      
Yes    971 (24)                                                                                                                                                                                              1.08 (0.99-1.19)                              1.09 (0.99-1.20)                                    1.07 (0.98-1.17)                                                                                                                  1.08 (0.99-1.18)                                                                                              
       
Colorectal No  45667 (75)                                                                                                                                                                                              1.00 (reference)                                                                                        1.00 (reference)                                            1.00 (reference)                                              1.00 (reference)                                                                                      
Yes  15232 (25)                                                                                                                                                                                              1.02 (0.99-1.06)                              1.02 (0.99-1.05)                                    1.02 (1.00-1.05)                                                                                                                1.02 (0.99-1.05)                                                                                                 
       
Head-neck No   4076 (77)                                                                                                                                                                                              1.00 (reference)                                                                                                                                                                                         1.00 (reference)                                    1.00 (reference)                                                1.00 (reference)                                                                                        
Yes   1247 (23)                                                                                                                                                                                              1.03 (0.92-1.17)                              1.05 (0.93-1.18)                                    1.02 (0.92-1.12)                                                                             1.04 (0.94-1.15)                                                                                                                       
       
Lung No   1877 (74)                                                                                                                                                                                              1.00 (reference)                                                                                                                                                      1.00 (reference)                                            1.00 (reference)                                              1.00 (reference)                                                                                      
Yes    660 (26)                                                                                                                                                                                              1.13 (0.99-1.28)                              1.10 (0.97-1.26)                                    1.09 (0.96-1.23)                                                                                                                  1.06 (0.94-1.20)                                                                                              
       
Thyroid No   3843 (82)                                                                                                                                                                                              1.00 (reference)                                                                                                                                                                                         1.00 (reference)                                    1.00 (reference)                                                 1.00 (reference)                                                                                       
Yes    848 (18)                                                                                                                                                                                              1.46 (1.17-1.81)                              1.19 (0.95-1.48)                                    1.33 (1.12-1.59)                                                                                                                  1.08 (0.91-1.29)                                                                                              
       
Breast No  61050 (77)                                                                                                                                                                                              1.00 (reference)                                                                                        1.00 (reference)                                            1.00 (reference)                                              1.00 (reference)                                                                                      
Yes  17774 (23)                                                                                                                                                                                              1.07 (1.02-1.12)                              1.08 (1.03-1.13)                                    1.04 (1.01-1.08)                                                                                                                1.05 (1.01-1.08)                                                                                                 
       
Kidney-bladder 
 
No   7026 (78)                                                                                                                                                                                              1.00 (reference)                                                                                                                                                                                         1.00 (reference)                                    1.00 (reference)                                                    1.00 (reference)                                                                                
Yes   2018 (22)                                                                                                                                                                                              1.09 (1.00-1.19)                              1.10 (1.01-1.20)                                    1.05 (0.98-1.13)                                                                    1.08 (1.00-1.16)                                                                                                                             
       
Prostate No  23911 (84)                                                                                                                                                                                              1.00 (reference)                                                                                          1.00 (reference)                                           1.00 (reference)                                             1.00 (reference)                                                                                   
Yes   4570 (16)                                                                                                                                                                                              0.96 (0.77-1.19)                              0.97 (0.78-1.20)                                    0.96 (0.85-1.10)                                                                             0.98 (0.86-1.12)                                                                                                                       
       
Ovary-uterus No  21804 (75)                                                                                                                                                                                              1.00 (reference)                                                                                             1.00 (reference)                                             1.00 (reference)                                             1.00 (reference)                                                                                           
Yes   7127 (25)                                                                                                                                                                                              1.04 (0.98-1.10)                              1.02 (0.97-1.08)                                    1.05 (1.01-1.10)                                                                           1.03 (0.98-1.08)                                                                                                                    
           
* Multivariable adjustment for age at surgery (continuous variable), sex (male or female), 
comorbidity (Charlson index 0, 1, or ≥2), hospital volume (in quartiles for each cancer group), and 
calendar year of surgery (1997-2002, 2003- 2008, or 2009-2014). 
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Table 3. Timing of cancer surgery within the narrow holiday period (7-wek period, 25th June to 15th 
August) and risk of mortality, expressed as hazard ratio (HR) with 95% confidence interval (CI).  
Cancer  Narrow 
holiday 
period   
Patients 
Number (%) 
Disease-specific mortality All-cause mortality 
Crude HR (95% 
CI) 
Adjusted HR 
(95% CI)* 
Crude HR (95% 
CI) 
Adjusted HR 
(95% CI)* 
Esophago-
gastric 
No 5333 (87) 1.00 (reference)                                                                                                                                                                                         1.00 (reference)                                    1.00 (reference)                                                                          1.00 (reference)                                                                                                               
Yes 791 (13) 1.00 (0.91-1.10)                                                                                                                                                                                         0.98 (0.89-1.07)                                    0.99 (0.91-1.08)                                        0.97 (0.89-1.06)                                                                                                                                     
       
Liver-pancreas-
biliary  
No 3585 (88) 1.00 (reference)                                                                                                                                                                                         1.00 (reference)                                    1.00 (reference)                                                                          1.00 (reference)                                                                                                               
Yes 488 (12) 1.12 (0.99-1.26)                                                                                                                                                                                         1.12 (0.99-1.26)                                    1.10 (0.98-1.24)                                        1.11 (0.99-1.24)                                                                                                                                                       
       
Colorectal No 52321 (86) 1.00 (reference)                                                                                                                                                                                         1.00 (reference)                                    1.00 (reference)                                                                          1.00 (reference)                                                                                                               
Yes 8578 (14) 1.01 (0.97-1.05)                                                                                                                                                                                         1.00 (0.96-1.04)                                    1.02 (0.99-1.06)                                                            1.02 (0.98-1.05)                                                                                                      
       
Head-neck No 4633 (87) 1.00 (reference)                                                                                                                                                                                         1.00 (reference)                                    1.00 (reference)                                                                          1.00 (reference)                                                                                                               
Yes 690 (13) 1.03 (0.89-1.21)                                                                                                                                                                                         1.02 (0.88-1.19)                                    1.03 (0.91-1.17)                                        1.02 (0.90-1.16)                                                                                                                                     
       
Lung No 2170 (86) 1.00 (reference)                                                                                                                                                                                         1.00 (reference)                                    1.00 (reference)                                                                          1.00 (reference)                                                                                                               
Yes 367 (14) 1.09 (0.93-1.28)                                                                                                                                                                                         1.07 (0.91-1.25)                                    1.06 (0.91-1.23)                                        1.03 (0.89-1.20)                                                                                                                                     
       
Thyroid No 4276 (91) 1.00 (reference)                                                                                                                                                                                         1.00 (reference)                                    1.00 (reference)                                                                          1.00 (reference)                                                                                                               
Yes       415 (9) 1.53 (1.16-2.03)                                                                                                                                                                                         1.27 (0.95-1.69)                                    1.38 (1.10-1.74)                                                            1.12 (0.89-1.42)                                                                                                                
       
Breast No 69014 (88) 1.00 (reference)                                                                                                                                                                                         1.00 (reference)                                    1.00 (reference)                                                                          1.00 (reference)                                                                                                               
Yes 9810 (12) 1.06 (1.01-1.12)                                                                                                                                                                                         1.06 (1.01-1.12)                                    1.03 (0.99-1.08)                                        1.02 (0.98-1.07)                                                                                                                                     
       
Kidney-bladder No 7934 (88) 1.00 (reference)                                                                                                                                                                                         1.00 (reference)                                    1.00 (reference)                                                                          1.00 (reference)                                                                                                               
Yes 1110 (12) 1.03 (0.92-1.15)                                                                                                                                                                                         1.05 (0.94-1.17)                                    0.99 (0.90-1.09)                                        1.03 (0.93-1.13)                                                                                                                                     
       
Prostate No 26410 (93) 1.00 (reference)                                                                                                                                                                                         1.00 (reference)                                    1.00 (reference)                                                                          1.00 (reference)                                                                                                               
Yes    2071 (7) 1.11 (0.84-1.47)                                                                                                                                                                                         1.10 (0.83-1.46)                                    0.99 (0.83-1.19)                                        0.98 (0.82-1.18)                                                                                                                                     
       
Ovary-uterus No 24993 (86) 1.00 (reference)                                                                                                                                                                                         1.00 (reference)                                    1.00 (reference)                                                                          1.00 (reference)                                                                                                               
Yes 3938 (14) 0.99 (0.92-1.06)                                                                                                                                                                                         0.96 (0.90-1.03)                                    1.03 (0.97-1.09)                                                     0.99 (0.94-1.05)                                                                                                                                          
 
* Multivariable adjustment for age at surgery (continuous variable), sex (male or female), 
comorbidity (Charlson index 0, 1, or ≥2), hospital volume (in quartiles for each cancer group), and 
calendar year of surgery (1997-2002, 2003- 2008, or 2009-2014). 
         
 
 
 
 
 
 
 
 
 
 
20 
 
Table 4. Timing of surgery within wide and narrow holiday periods and disease-specific mortality, 
stratified by dichotomized covariates, expressed as adjusted hazard ratio (HR) with 95% confidence 
interval (CI). 
Cancer Covariate Wide holiday period† Narrow holiday period§ 
No Yes No Yes 
HR (95 % CI) HR (95 % CI)* HR (95 % CI) HR (95 % CI)* 
Esophago-
gastric 
Age (years) <65 1.00 (reference) 0.98 (0.86-1.12) 1.00 (reference) 1.03 (0.87-1.21) 
≥65 1.00 (reference) 1.01 (0.92-1.10) 1.00 (reference) 0.95 (0.85-1.07) 
Sex Male 1.00 (reference) 1.00 (0.91-1.10) 1.00 (reference) 0.94 (0.84-1.06) 
Female 1.00 (reference) 0.99 (0.87-1.13) 1.00 (reference) 1.04 (0.89-1.22) 
Comorbidity 
score 
0 1.00 (reference) 1.01 (0.92-1.12) 1.00 (reference) 1.02 (0.90-1.15) 
≥1 1.00 (reference) 0.97 (0.87-1.09) 1.00 (reference) 0.92 (0.79-1.06) 
Hospital 
volume 
(quartiles) 
1+2 1.00 (reference) 1.00 (0.91-1.11) 1.00 (reference) 0.94 (0.82-1.06) 
3+4 1.00 (reference) 0.99 (0.89-1.11) 1.00 (reference) 1.03 (0.89-1.18) 
Calendar 
period 
1997-2005 1.00 (reference) 0.99 (0.90-1.09) 1.00 (reference) 0.95 (0.84-1.07) 
2006-2014 1.00 (reference) 1.04 (0.92-1.17) 1.00 (reference) 1.06 (0.92-1.23) 
       
Liver-
pancreas-
biliary  
Age (years) <65 1.00 (reference) 1.06 (0.91-1.23) 1.00 (reference) 1.06 (0.87-1.28) 
≥65 1.00 (reference) 1.10 (0.98-1.24) 1.00 (reference) 1.16 (0.99-1.35) 
Sex Male 1.00 (reference) 1.22 (1.08-1.39) 1.00 (reference) 1.21 (1.02-1.43) 
Female 1.00 (reference) 0.97 (0.85-1.11) 1.00 (reference) 1.04 (0.88-1.23) 
Comorbidity 
score 
0 1.00 (reference) 1.03 (0.91-1.17) 1.00 (reference) 1.02 (0.87-1.21) 
≥1 1.00 (reference) 1.17 (1.02-1.35) 1.00 (reference) 1.25 (1.05-1.48) 
Hospital 
volume 
(quartiles) 
1+2 1.00 (reference) 1.06 (0.94-1.21) 1.00 (reference) 1.08 (0.92-1.27) 
3+4 1.00 (reference) 1.12 (0.98-1.28) 1.00 (reference) 1.17 (0.98-1.39) 
Calendar 
period 
1997-2005 1.00 (reference) 1.07 (0.92-1.23) 1.00 (reference) 1.13 (0.94-1.36) 
2006-2014 1.00 (reference) 1.11 (0.98-1.25) 1.00 (reference) 1.12 (0.95-1.31) 
       
Colorectal Age (years) <65 1.00 (reference) 1.06 (0.99-1.13) 1.00 (reference) 1.03 (0.95-1.12) 
≥65 1.00 (reference) 1.01 (0.98-1.05) 1.00 (reference) 1.00 (0.95-1.04) 
Sex Male 1.00 (reference) 1.01 (0.96-1.05) 1.00 (reference) 1.00 (0.94-1.05) 
Female 1.00 (reference) 1.03 (0.98-1.08) 1.00 (reference) 1.01 (0.95-1.07) 
Comorbidity 
score 
0 1.00 (reference) 1.00 (0.96-1.04) 1.00 (reference) 0.95 (0.90-1.00) 
≥1 1.00 (reference) 1.05 (1.00-1.10) 1.00 (reference) 1.08 (1.02-1.15) 
Hospital 
volume 
(quartiles) 
1+2 1.00 (reference) 0.98 (0.94-1.03) 1.00 (reference) 0.97 (0.91-1.02) 
3+4 1.00 (reference) 1.05 (1.01-1.10) 1.00 (reference) 1.04 (0.98-1.10) 
Calendar 
period 
1997-2005 1.00 (reference) 0.99 (0.95-1.03) 1.00 (reference) 0.96 (0.91-1.01) 
2006-2014 1.00 (reference) 1.07 (1.02-1.12) 1.00 (reference) 1.08 (1.01-1.15) 
       
Head-neck  Age (years) <65 1.00 (reference) 1.05 (0.87-1.26) 1.00 (reference) 0.91 (0.71-1.17) 
≥65 1.00 (reference) 1.05 (0.89-1.23) 1.00 (reference) 1.11 (0.91-1.35) 
Sex Male 1.00 (reference) 1.07 (0.92-1.24) 1.00 (reference) 0.97 (0.80-1.18) 
Female 1.00 (reference) 1.01 (0.82-1.25) 1.00 (reference) 1.13 (0.87-1.47) 
Comorbidity 
score 
0 1.00 (reference) 1.06 (0.91-1.24) 1.00 (reference) 1.01 (0.83-1.23) 
≥1 1.00 (reference) 1.02 (0.84-1.24) 1.00 (reference) 1.04 (0.82-1.33) 
Hospital 1+2 1.00 (reference) 1.31 (1.09-1.56) 1.00 (reference) 1.25 (1.01-1.57) 
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volume 
(quartiles) 
3+4 1.00 (reference) 0.87 (0.73-1.03) 1.00 (reference) 0.85 (0.69-1.06) 
Calendar 
period 
1997-2005 1.00 (reference) 1.02 (0.86-1.20) 1.00 (reference) 0.94 (0.76-1.16) 
2006-2014 1.00 (reference) 1.08 (0.91-1.30) 1.00 (reference) 1.12 (0.90-1.40) 
       
Lung Age (years) <65 1.00 (reference) 1.08 (0.89-1.32) 1.00 (reference) 1.04 (0.81-1.34) 
≥65 1.00 (reference) 1.12 (0.94-1.33) 1.00 (reference) 1.08 (0.88-1.34) 
Sex Male 1.00 (reference) 1.07 (0.91-1.26) 1.00 (reference) 1.11 (0.90-1.36) 
Female 1.00 (reference) 1.16 (0.94-1.42) 1.00 (reference) 1.00 (0.77-1.30) 
Comorbidity 
score 
0 1.00 (reference) 1.09 (0.92-1.30) 1.00 (reference) 1.09 (0.88-1.35) 
≥1 1.00 (reference) 1.11 (0.92-1.36) 1.00 (reference) 1.03 (0.80-1.33) 
Hospital 
volume 
(quartiles) 
1+2 1.00 (reference) 1.08 (0.90-1.31) 1.00 (reference) 1.05 (0.83-1.33) 
3+4 1.00 (reference) 1.11 (0.93-1.33) 1.00 (reference) 1.08 (0.86-1.35) 
Calendar 
period 
1997-2005 1.00 (reference) 1.16 (0.98-1.37) 1.00 (reference) 1.11 (0.90-1.36) 
2006-2014 1.00 (reference) 1.04 (0.84-1.28) 1.00 (reference) 1.03 (0.79-1.34) 
       
Thyroid Age (years) <65 1.00 (reference) 1.25 (0.78-2.00) 1.00 (reference) 1.35 (0.74-2.46) 
≥65 1.00 (reference) 1.28 (1.00-1.64) 1.00 (reference) 1.33 (0.96-1.83) 
Sex Male 1.00 (reference) 1.18 (0.82-1.70) 1.00 (reference) 1.25 (0.79-2.00) 
Female 1.00 (reference) 1.20 (0.91-1.58) 1.00 (reference) 1.28 (0.89-1.83) 
Comorbidity 
score 
0 1.00 (reference) 1.29 (0.98-1.69) 1.00 (reference) 1.44 (1.01-2.06) 
≥1 1.00 (reference) 1.04 (0.71-1.51) 1.00 (reference) 1.04 (0.65-1.67) 
Hospital 
volume 
(quartiles) 
1+2 1.00 (reference) 1.06 (0.76-1.47) 1.00 (reference) 1.18 (0.76-1.82) 
3+4 1.00 (reference) 1.32 (0.98-1.78) 1.00 (reference) 1.35 (0.93-1.97) 
Calendar 
period 
1997-2005 1.00 (reference) 1.05 (0.78-1.42) 1.00 (reference) 1.17 (0.80-1.71) 
2006-2014 1.00 (reference) 1.41 (1.02-1.96) 1.00 (reference) 1.41 (0.92-2.17) 
       
Breast Age (years) <65 1.00 (reference) 1.06 (0.99-1.13) 1.00 (reference) 1.07 (0.99-1.16) 
≥65 1.00 (reference) 1.09 (1.03-1.16) 1.00 (reference) 1.06 (0.98-1.14) 
Comorbidity 
score 
0 1.00 (reference) 1.07 (1.02-1.13) 1.00 (reference) 1.08 (1.01-1.15) 
≥1 1.00 (reference) 1.09 (1.01-1.19) 1.00 (reference) 1.02 (0.92-1.14) 
Hospital 
volume 
(quartiles) 
1+2 1.00 (reference) 1.08 (1.02-1.14) 1.00 (reference) 1.09 (1.01-1.17) 
3+4 1.00 (reference) 1.07 (1.00-1.14) 1.00 (reference) 1.03 (0.94-1.12) 
Calendar 
period 
1997-2005 1.00 (reference) 1.08 (1.02-1.13) 1.00 (reference) 1.05 (0.99-1.13) 
2006-2014 1.00 (reference) 1.09 (1.00-1.18) 1.00 (reference) 1.09 (0.99-1.20) 
       
Kidney-
bladder 
Age (years) <65 1.00 (reference) 1.12 (0.97-1.28) 1.00 (reference) 1.08 (0.90-1.28) 
≥65 1.00 (reference) 1.08 (0.96-1.20) 1.00 (reference) 1.01 (0.88-1.16) 
Sex Male 1.00 (reference) 1.14 (1.02-1.27) 1.00 (reference) 1.12 (0.98-1.29) 
Female 1.00 (reference) 1.04 (0.90-1.21) 1.00 (reference) 0.93 (0.77-1.12) 
Comorbidity 
score 
0 1.00 (reference) 1.10 (0.99-1.23) 1.00 (reference) 0.99 (0.86-1.14) 
≥1 1.00 (reference) 1.10 (0.95-1.27) 1.00 (reference) 1.15 (0.97-1.38) 
Hospital 
volume 
(quartiles) 
1+2 1.00 (reference) 0.96 (0.84-1.10) 1.00 (reference) 0.85 (0.72-1.01) 
3+4 1.00 (reference) 1.22 (1.09-1.37) 1.00 (reference) 1.25 (1.08-1.44) 
Calendar 
period 
1997-2005 1.00 (reference) 0.99 (0.88-1.11) 1.00 (reference) 0.92 (0.79-1.07) 
2006-2014 1.00 (reference) 1.27 (1.11-1.44) 1.00 (reference) 1.25 (1.06-1.47) 
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Prostate  Age (years) <65 1.00 (reference) 0.84 (0.61-1.15) 1.00 (reference) 0.83 (0.53-1.30) 
≥65 1.00 (reference) 1.09 (0.81-1.45) 1.00 (reference) 1.36 (0.94-1.96) 
Comorbidity 
score 
0 1.00 (reference) 0.93 (0.73-1.19) 1.00 (reference) 1.02 (0.73-1.43) 
≥1 1.00 (reference) 1.11 (0.73-1.71) 1.00 (reference) 1.36 (0.80-2.31) 
Hospital 
volume 
(quartiles) 
1+2 1.00 (reference) 1.00 (0.74-1.36) 1.00 (reference) 0.91 (0.59-1.40) 
3+4 1.00 (reference) 0.95 (0.70-1.28) 1.00 (reference) 1.32 (0.91-1.92) 
Calendar 
period 
1997-2005 1.00 (reference) 0.89 (0.67-1.17) 1.00 (reference) 0.85 (0.58-1.26) 
2006-2014 1.00 (reference) 1.15 (0.82-1.63) 1.00 (reference) 1.63 (1.07-2.47) 
       
Ovary-
uterus 
Age (years) <65 1.00 (reference) 1.02 (0.94-1.11) 1.00 (reference) 0.93 (0.84-1.04) 
≥65 1.00 (reference) 1.02 (0.96-1.10) 1.00 (reference) 0.99 (0.90-1.08) 
Comorbidity 
score 
0 1.00 (reference) 1.02 (0.96-1.09) 1.00 (reference) 0.94 (0.86-1.02) 
≥1 1.00 (reference) 1.02 (0.92-1.13) 1.00 (reference) 1.03 (0.91-1.16) 
Hospital 
volume 
(quartiles) 
1+2 1.00 (reference) 0.99 (0.92-1.07) 1.00 (reference) 0.96 (0.87-1.06) 
3+4 1.00 (reference) 1.05 (0.98-1.13) 1.00 (reference) 0.97 (0.88-1.07) 
Calendar 
period 
1997-2005 1.00 (reference) 1.02 (0.95-1.09) 1.00 (reference) 0.91 (0.84-1.00) 
2006-2014 1.00 (reference) 1.03 (0.94-1.12) 1.00 (reference) 1.03 (0.93-1.15) 
 
* Multivariable adjustment for age at surgery (continuous variable), sex (male or female), 
comorbidity (Charlson index 0, 1, or ≥2), hospital volume (in quartiles for each cancer group), and 
calendar year of surgery (1997-2002, 2003- 2008, or 2009-2014). 
†Wide holiday period is period from 16th June to 31st August and 16th December to 7th January. 
§ Narrow holiday period is period from 25th June to 15th August. 
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Figure legends 
Supplementary Figure 1. Kaplan-Meier curves of the crude disease-specific mortality in 
cancer of the liver-pancreas-biliary tract following surgery conducted during wide holiday 
periods (1A) and narrow holiday periods (1B).  
 
Supplementary Figure 2. Kaplan-Meier curves of the crude disease-specific mortality in 
cancer of the breast following surgery conducted during wide holiday periods (2A) and 
narrow holiday periods (2B).  
 
 
